App-Quantinova.ai

Risk stratifying patients presenting with lymphadenopathy – an audit of 2 weeks wait referrals for suspected haematological malignancy compared to NICE guidance

M. Cant - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

N/A

Vaccination recommendation in newly diagnosed chronic lymphocytic leukaemia: a retrospective audit

R. Jones - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Chronic Lymphocytic Leukemia

Pneumococcal Vaccine Polyvalent

Implementing venetoclax treatment into day case setting for patients at high risk of tumour lysis syndrome; University Hospital Southampton NHS Foundation Trust experience

K. Matulay - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Venetoclax

18Fluoromethylcholine –positron emission tomography computed tomography is not inferior to gadolinium‐enhanced magnetic resonance imaging in central nervous system lymphoma imaging

K. Marshall - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Choline bitartrate

Local experience of the use of IVE methotrexate chemotherapy for the treatment of systemic T‐cell lymphoma

T. Fail - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Peripheral T-cell lymphoma

Methotrexate

Indirect treatment comparison analysis of venetoclax + obinutuzumab with standard front‐line regimens for chronic lymphocytic leukaemia

N. Coll Bastus - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the United Kingdom

J. Xie - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Is the all‐oral DEVEC metronomic schedule a better alternative to infusional chemotherapy protocols in elderly with peripheral T‐cell lymphoma?

M. C. Cox - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Vinorelbine

Exercise training is a feasible and active complementary therapy in adult and elderly patients receiving anti‐lymphoma treatments

M. C. Cox - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Anthracycline prescribing in lymphoma: traffic light guidance using NT‐proBNP and echocardiogram

K. Nyunt - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cardiotoxicity

N/A

Post discharge care needs for patients with treated Primary CNS Lymphoma – a baseline single centre retrospective study

E. Omer - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Primary central nervous system lymphoma

Methotrexate

Palliative care needs during inpatient stay for commercial chimeric antigen receptor T‐cell infusion at the Newcastle‐Upon‐Tyne Hospitals NHS Foundation Trust

K. Smith - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

B cell lymphomas

N/A

Experiences of providing commercial Chimeric Antigen Receptor (CAR‐T) cell therapy at the Northern Centre for Cancer Care

K. Smith - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Axicabtagene ciloleucel

Btk inhibitors ibrutinib and acalabrutinib impair FcγRIIa‐mediated responses of healthy donor platelets and chronic lymphocytic leukaemia platelets to bacteria

L. Naylor-Adamson - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

ACOPP chemotherapy for front‐line treatment of older patients with Hodgkin lymphoma – a pilot study

M. Wilson - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hodgkin's Lymphoma

Cyclophosphamide

A retrospective study to look at outcomes of those over 80 treated with RCHOP chemotherapy

D. Gordon-Walker - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Incidence of cardiotoxicity in anthracycline‐based chemotherapy in lymphoma patients: a single centre experience

C. Bloodworth - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Cyclophosphamide

A single centre experience of using ciclosporin and mycophenolate mofetil immunosuppression in relapsed/refractory angio‐immunoblastic T‐cell lymphoma

K. De Abrew - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Autoimmune hemolytic anemia

Mycophenolate mofetil

Single centre experience of efficacy and tolerability of attenuated immunochemotherapy (R‐miniCHOP) in elderly patients with high‐grade non‐Hodgkin lymphoma

S. Idris - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non‐Hodgkin Lymphoma

Cyclophosphamide

Treatment decisions in Waldenstrom's Macroglobulinaemia; outcomes from the South East Scotland Cancer Network

A. Duguid - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Non‐Hodgkin Lymphoma

Cyclophosphamide

Filters

45280 Abstracts